Succinate Dehydrogenase-Deficient Renal Cell Carcinoma

23Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

Succinate dehydrogenase (SDH)-deficient renal cell carcinoma is a recently recognized distinct subtype of renal cell carcinoma in the 2016 World Health Organization classification. It is associated with SDH gene germline mutations, which also cause paraganglioma/pheochromocytoma, gastrointestinal stromal tumor, and pituitary adenoma. The tumor most commonly presents in young adulthood. The tumors are arranged in solid nests or in tubules and frequently show cystic change. The tumors are composed of cuboidal to oval cells with round nuclei, dispersed chromatin, and inconspicuous nucleoli. The cytoplasm is eosinophilic or flocculent but not truly oncocytic. The most distinctive histologic feature is the presence of cytoplasmic vacuoles or inclusions. Loss of SDH subunit B immunostaining is needed for a definite diagnosis. The prognosis is good for low-grade tumors but worse for tumors with high-grade nuclei, sarcomatoid change, or coagulative necrosis. Long-term follow-up is indicated.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Tsai, T. H., & Lee, W. Y. (2019, May 1). Succinate Dehydrogenase-Deficient Renal Cell Carcinoma. Archives of Pathology & Laboratory Medicine. NLM (Medline). https://doi.org/10.5858/arpa.2018-0024-RS

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

56%

Lecturer / Post doc 2

22%

Researcher 2

22%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

88%

Biochemistry, Genetics and Molecular Bi... 2

12%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 285

Save time finding and organizing research with Mendeley

Sign up for free